[beta2-Microglobulin and monoclonal gammapathies (author's transl)]

Area of Science:

• Clinical Chemistry
• Immunology
• Nephrology

Context:

• Monoclonal gammopathies are a diverse group of disorders characterized by the production of a monoclonal immunoglobulin.
• Beta-2 microglobulin (beta2m) is a protein found on the surface of most nucleated cells, and its serum levels can be affected by cell turnover and kidney function.

Purpose:

• To investigate the diagnostic utility of beta-2 microglobulin (beta2m) levels in patients with monoclonal gammopathies.
• To assess the correlation between beta2m levels and the presence of renal failure in monoclonal gammopathy patients.
• To evaluate differences in beta2m levels across various immunoglobulin subtypes of monoclonal gammopathies.

Summary:

• Beta-2 microglobulin (beta2m) levels were significantly higher in 111 patients with monoclonal gammopathy (M = 4.75 mg/l) compared to normal subjects (M = 1.38 mg/l).
• Patients with monoclonal gammopathy and renal failure exhibited higher beta2m levels (M = 7.07 mg/l) than those with renal failure alone (M = 3.45 mg/l), with statistical significance (p = 0.005).
• While beta2m levels were highest in IgA monoclonal gammopathies, the differences among IgA, IgG, and IgM subtypes were not statistically significant. Beta2m assay did not differentiate myeloma from benign monoclonal gammopathy.

Impact:

• Beta-2 microglobulin serves as a valuable biomarker for detecting monoclonal gammopathies and assessing renal involvement.
• The findings highlight the importance of monitoring beta2m levels in patients with monoclonal gammopathies, particularly those with kidney complications.
• Further research may explore the role of beta2m in conjunction with other markers for improved diagnostic accuracy in complex cases.